How Medical Animation Can Support Investor Relations Activities?
Medical animation is the perfect tool for investor relations activities, helping to visually convey complex science and data in an easy-to-understand and engaging way. Portraying an accurate account of scientific concepts enables potential investors to make informed decisions on their investments. Investment is crucial for biotechnology companies to run clinical trials, carry out research and develop successful drugs.
As a drug moves through phases of clinical trials, funding needs, decision-makers and stakeholders will differ, meaning the assets needed for investor relations will need to adapt to these changes. Effective scientific communication helps investors understand and visualize the science behind a concept, disease, drug, or product.
3D animation brings science to life, beautifully conveying key messages behind pipelines and products. Enabling investors to grasp complicated scientific matters and understand intricate drug pathways is vital for the success of gaining investor funding and interest.
Those in an investor relations role need to help investors make educated decisions on whether to invest. Medical animation provides insight into the need for research and treatment of diseases, going beyond just monetary value. Commissioning a mechanism of action (MoA) or disease awareness animation is an effective tool, helping pharma and biotech companies secure the funding that they need to continue research and development, and in turn, boosting return on investment (ROI).
3D medical animation is an effective way of making science engaging and easy to watch. Our specialist team consists of PhD scientists, artists, animators, and programmers, who collaborate to effortlessly intertwine the worlds of science, art, and technology, producing some of the most impactful scientific imagery, stories, and interactive experiences.
An animation can be tailored so that it is suitable for a variety of target audiences. Complex scientific concepts can be explained at a high level and later simplified into lay terms so that your assets can be utilized for all audiences.
When it comes to investor relations activities, assets from a medical animation can be leveraged across all corporate materials to give a stand-out, memorable and professional look and feel. Imagery and stills from the animation can amp up slide decks to create cohesive content and enhance visual brand identity. When presenting to potential investors, an animation can transform complicated science into a narrative that can be easily understood, regardless of background knowledge. Medical animation is an effective means of exhibiting the science to a molecular level so that investors have a complete understanding.
When commissioning an animation with Random42 you will be offered a complimentary visual toolkit that includes animation stills, imagery on a transparent background, and short clips around 10 seconds in length. These assets can be utilized for social media channels, website content, press releases, slide decks, presentations, and event booth backdrops.
Furthermore, medical animation can be leveraged into interactive experiences. Virtual reality (VR) and augmented reality (AR) are popular technologies used to bring science even further to life. At a meeting or event, a VR headset or AR device can be used and can transport the viewer into the body, making it the perfect scientific visualization tool. As a drug moves along the pipeline the initial animation can be developed into an interactive experience as the project’s needs change.
The use of medical animation for investor relations activities is highly beneficial for captivating attention, aiding understanding, and stimulating interest. It allows investors to make more confident and informed decisions by helping them to understand the diseases and drugs that they are financially backing.
Get in touch with our specialist team today to see how we can help your next scientific animation project come to life and support your investor relations needs at all pipeline phases.